Dr. Stein is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
840 US Highway 1
Ste 235
North Palm Beach, FL 33408Phone+1 561-626-2006Fax+1 561-624-9718
Education & Training
Fitzsimons Army Medical CenterResidency, Internal Medicine, 1975 - 1977
Letterman Army Medical CenterResidency, Internal Medicine, 1972 - 1975
University of Colorado School of Medicine/National Jewish Health (Adult)Residency, Allergy and Immunology, 1968 - 1970- Abington Memorial HospitalInternship, Transitional Year, 1968 - 1969
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1968
Certifications & Licensure
CA State Medical License 1971 - Present
FL State Medical License 1979 - 2025
PA State Medical License 1969 - 1992
MD State Medical License 1977 - 1983
CO State Medical License 1975 - 1979- American Board of Allergy and Immunology Allergy & Immunology
- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- Top MD Consumers Checkbook
- Whos Who in Medicine and Healthcare Marquis Whos Who
- Fellow (FAAAAI) American Academy of Allergy Asthma and Immunology
Clinical Trials
- Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma Start of enrollment: 2008 Aug 18
- Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Start of enrollment: 2009 Jul 01
- Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases Start of enrollment: 2014 Feb 01
Publications & Presentations
PubMed
- 4 citationsInfection rates and tolerability of three different immunoglobulin administration modalities in patients with primary immunodeficiency diseases.Richard L Wasserman, Sudhir Gupta, Mark Stein, Christopher J Rabbat, Werner Engl
Immunotherapy. 2022-03-01 - 4 citationsImmune globulin subcutaneous, human - klhw 20% for primary humoral immunodeficiency: an open-label, Phase III study.John W. Sleasman, William R. Lumry, I. Hussain, H. James Wedner, James B Harris
Immunotherapy. 2019-10-17 - 9 citationsSafety and tolerability of subcutaneous immunoglobulin 20% in primary immunodeficiency diseases from two continentsDaniel Suez, Gergely Kriván, Stephen Jolles, Mark R. Stein, Sudhir Gupta
Immunotherapy. 2019-07-03
Press Mentions
![CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] Data Demonstrate Improved Treatment Satisfaction Relative to Patients’ Previous Immunoglobulin Therapy](https://doximity-res.cloudinary.com/image/upload/caaqncz0d1o4c2llvohh.png)
CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] Data Demonstrate Improved Treatment Satisfaction Relative to Patients’ Previous Immunoglobulin TherapyMarch 6th, 2017
Efficacy, Safety, Tolerability, and Pharmacokinetics of Human Immune Globulin Subcutaneous, 20% (IGSC 20%): Final Analysis of a Phase 2/3 Study in Patients with Primary Immunodeficiency Disease (PIDD) in North AmericaMarch 7th, 2016
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
